Not Yet RecruitingNot Applicable

Fractional Exhaled Nitric Oxide and Exacerbations of COPD

Taiwan120 participantsStarted 2026-03-01

Plain-language summary

Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition with recurrent exacerbations despite guideline-based therapy. This prospective observational cohort study aims to evaluate whether baseline fractional exhaled nitric oxide (FeNO), a biomarker of type 2 airway inflammation, predicts future exacerbations and lung function decline in COPD patients initiated on triple inhaler therapy in routine clinical practice. The study will also explore the relationships between air pollution exposure, type 2 inflammatory biomarkers, and COPD outcomes.

Who can participate

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged 40 years or older * Diagnosis of chronic obstructive pulmonary disease (COPD) confirmed by post-bronchodilator spirometry (FEV₁/FVC \< 0.70). * History of cigarette smoking * Receiving triple inhaler therapy (inhaled corticosteroid/long-acting beta-agonist/long-acting muscarinic antagonist) as part of routine clinical care, including: * patients who have been previously escalated to triple inhaler therapy due to prior exacerbations and are already receiving triple therapy at the time of enrollment, and * patients who are newly prescribed triple inhaler therapy at or immediately before enrollment because of a recent exacerbation. Exclusion Criteria: \-

What they're measuring

Annualized rate of moderate-to-severe COPD exacerbations

Timeframe: Up to 12 months after enrollment

Trial details

NCT IDNCT07396311

SponsorChang Gung Memorial Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-02-29

Contact for this trial

Ting-Yu Lin, MD

+886-3-3281200 h12519@cgmh.org.tw